Importantly, hyperglycemia was not commonly seen in patients in Phase I dose escalation trials of IGF-1/2 neutralizing antibodies MEDI-573 (dusigitumab) [166,167] and BI 836845 (xentuzumab) [168], suggesting that anti-IGF-1/2 therapies may have a better metabolic safety profile compared to anti-IGF-1R antibodies or IGF-1R RTKi. The gene discussed is IGF1R; the disease is Hyperglycemia.